NewsSource: EClinCloud

Get the “Latest” Key Takeaways on “Patient-Centered” Guidelines

4 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.

Article image

.


Hello everybody!

Article image


Article image

In July of this year, the CDE officially issued three “patient-centered” guidelines covering clinical trial design, implementation, and benefit-risk assessment. They propose conducting drug development, trial design, implementation, and decision-making from the patient’s perspective, and advocate providing clinical outcome assessment (COA) in trials for efficacy or safety evaluation, aiming to efficiently develop clinically valuable drugs that better meet patient needs.



So our editor studied them in depth, thoroughly learning and understanding the guiding principles and key contents, and finally connected the dots!Article image


Specifically, three keywords dominate the screen:


Article image

Patient-Centered

Patient Experience Data

Clinical Outcome Assessment (COA)


Our editor counted on their fingers how many times these terms appear in the guidelines—that alone shows how important they are. Based on those frequencies, they are practically trending topics!Article image


Patient-Centered



Guideline 1

18 times

Guideline 2

18 times

Guideline 3

8 times

Article image

Total

44 times


Patient Experience Data



Guideline 1

31 times

Guideline 2

8 times

Guideline 3

57 times

Total

96 times


Clinical Outcome Assessment (COA)



Guideline 1

68 times

Guideline 2

11 times

Guideline 3

20 times

Total

99 times


Based on the above, our editor has summarized the core contents of the three guidelines and analyzed them from a personal perspective:


Guideline 1

Technical Guidelines for Patient-Centered Drug Clinical Trial Design


The main text has a total of 8873 characters, in which “clinical outcome assessment (COA)” appears a total of 68 times and “patient experience data” appears a total of 31 times—a remarkably high frequency. A substantial portion of the text focuses on the section “Efficacy Evaluation Based on Clinical Outcome Assessment (COA),” explaining the definition of clinical outcome assessment (COA), how to select scales under different circumstances, and approaches to establishing assessment endpoints, among other topics, emphasizing the need to prioritize the collection of patient data in clinical trials and carefully select appropriate, validated, and clinically meaningful scale instruments for evaluation.



Guideline 2

Technical Guidelines for Patient-Centered Drug Clinical Trial Implementation


The main text totals 9095 characters, in which "patient-centered" appears a total of 18 times and "clinical outcome assessment (COA)" appears a total of 11 times. In addition, we found that the text mentions "electronic" 22 times, describing that clinical trials should proceed from the patient's perspective and can use electronic methods to reduce patient burden while protecting patients' private data.



Guideline 3

Technical Guidelines for Patient-Centered Drug Benefit-Risk Assessment


The main text totals 7112 characters, in which "patient experience data" appears a total of 57 times and "clinical outcome assessment (COA)" appears a total of 20 times. The text divides patient experience data into two categories—clinical outcome assessment (COA) and patient preference information (PPI)—and recommends that when using a single scale as a single endpoint or combining multiple scales as a composite endpoint for assessment in clinical trials, information such as patient preferences and adherence should also be considered.



From this, we gained a clear takeaway Article image

Article image


"Patient-centered" clinical trials emphasize the capture and collection of patient experience data, encourage the use of clinical outcome assessment (COA) for efficacy and safety evaluations, and recommend that sponsors adopt validated electronic methods for data collection to reduce the burden on patients participating in clinical trials, improve clinical research quality and efficiency, and support new drug R&D and market approval.


Here Is the Key Point


EClinCloud provides one-stop scale management services and an electronic clinical outcome assessment (eCOA) system, has passed NMPA (CFDI) inspection, and has experience supporting drug approvals.


EClinCloud provides one-stop scale management services and an electronic clinical outcome assessment (eCOA) system, has passed NMPA (CFDI) inspection, and has experience supporting drug approvals.


EClinCloud provides one-stop scale management services and an electronic clinical outcome assessment (eCOA) system, has passed NMPA (CFDI) inspection, and has experience supporting drug approvals.




If you have any needs, please feel free to contact us anytime.

Article image



We have also excerpted the usage recommendations and advantages regarding eCOA from the guidelines for your reference.Article image

Article image

Article image

Article image

Article image





About EClinCloud

EClinCloud is a technology company focused on clinical R&D that provides an integrated, interconnected all-in-one cloud platform for clinical trials (including technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, with solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system and ophthalmology). Combining cutting-edge technology with life data, it is building a globally leading "patient-centered" clinical evidence support SaaS cloud platform to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market approval of drugs and medical devices, and benefit countless patients.






Article image

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.